Asia-Pacific ICP Monitoring Devices Sector Primed for Solid Growth

Solid growth is forecast for Asia-Pacific’s (APAC) intracranial pressure (ICP) monitoring devices market this decade as traumatic brain injuries and incidences of neurological disorders rise in the region.

Globaldata estimates the sector will rise 7 percent annually through 2030, driven by the world’s aging population and its subsequent impact on rising rates of traumatic brain injuries, intraventricular hemorrhages, infections, and neurodegenerative diseases.  

“The market in APAC is mainly driven by the burden of patients with neurological diseases such as congenital and acquired hydrocephalus, brain tumor, and cysts,” said Anusha Kaushik, a medical devices analyst at GlobalData. “Countries such as China and Japan are investing in national programs to improve their understanding of disorders associated with the brain. The most preferred technique for ICP monitoring is external ventricular drainage (EVD).”

GlobalData’s report, “ICP Monitoring Devices (Neurology Devices) – Global Market Analysis and Forecast Model (COVID-19 Market Impact),” reveals that Integra Lifesciences, Medtronic plc, and Natus Medical Inc. are the major players and together account for more than 60 percent of the APAC market in 2021. 
 
EVDs are considered the gold standard for ICP monitoring due to cost and the additional function of cerebrospinal drainage. Micro transducer devices are expensive and cannot be measured after implantation but are used when implantation of EVD is not possible and they have a lower risk of infection. The demand for EVD will increase in the coming years as they are more familiar to surgeons, less expensive, and provide better clinical outcomes. As positive results come through clinical trials, the demand for antimicrobial EVD will increase as they offer a lower risk of infection in comparison with regular EVD and micro transducers.
 
“Elevated levels of ICP have a bad impact on patients’ health. ICP monitoring helps in the detection of brain damage and helps in proper and effective treatment. As COVID-19 cases subside and vaccination of the general population continues, the backlog of elective procedure volumes for neurovascular surgeries are expected to recover,” Kaushik said.